Viridian Therapeutics, Inc./DE Interest Expense
Viridian Therapeutics, Inc./DE (VRDN) reported Interest Expense of $200.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2023-08-08
- Viridian Therapeutics, Inc./DE interest expense for the quarter ending 2023-06-30 was $200.00K, a 0.00% change year-over-year.
- Viridian Therapeutics, Inc./DE interest expense for the quarter ending 2023-03-31 was $200.00K.
- Viridian Therapeutics, Inc./DE interest expense for the quarter ending 2022-12-31 was $200.00K.
- Viridian Therapeutics, Inc./DE interest expense for the quarter ending 2022-09-30 was $200.00K.
- Viridian Therapeutics, Inc./DE interest expense for fiscal 2022 was $500.00K.
- Viridian Therapeutics, Inc./DE interest expense for fiscal 2016 was $95.00K, a 32.62% decline from fiscal 2015.
- Viridian Therapeutics, Inc./DE interest expense for fiscal 2015 was $141.00K, a 86.22% decline from fiscal 2014.
- Viridian Therapeutics, Inc./DE interest expense for fiscal 2014 was $1.02M, a 47.89% decline from fiscal 2013.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2023-06-30 | $200.00K 10-Q · filed 2023-08-08 | $300.00K 10-Q · filed 2023-08-08 | $600.00K derived: sum of 3 quarters · filed 2023-08-08 | $800.00K derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2023-03-31 | $200.00K 10-Q · filed 2023-05-10 | $400.00K derived: sum of 2 quarters · filed 2023-05-10 | $600.00K derived: sum of 3 quarters · filed 2023-05-10 | $800.00K derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $400.00K derived: sum of 2 quarters · filed 2023-03-09 | $600.00K derived: sum of 3 quarters · filed 2023-08-08 | $500.00K 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $200.00K 10-Q · filed 2022-11-14 | $400.00K derived: sum of 2 quarters · filed 2023-08-08 | $300.00K 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-08 | $200.00K 10-Q · filed 2023-08-08 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | ||||||
| 2016-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $49.00K derived: sum of 2 quarters · filed 2017-03-24 | $72.00K derived: sum of 3 quarters · filed 2017-03-24 | $95.00K 10-K · filed 2017-03-24 | |||
| 2016-09-30 | $23.00K 10-Q · filed 2016-10-26 | $46.00K derived: sum of 2 quarters · filed 2016-10-26 | $69.00K 10-Q · filed 2016-10-26 | $92.00K derived: sum of 4 quarters · filed 2017-03-24 | |||
| 2016-06-30 | $23.00K 10-Q · filed 2016-08-15 | $46.00K 10-Q · filed 2016-08-15 | $69.00K derived: sum of 3 quarters · filed 2017-03-24 | $93.00K derived: sum of 4 quarters · filed 2017-03-24 | |||
| 2016-03-31 | $23.00K 10-Q · filed 2016-05-16 | $46.00K derived: sum of 2 quarters · filed 2017-03-24 | $70.00K derived: sum of 3 quarters · filed 2017-03-24 | $142.00K derived: sum of 4 quarters · filed 2017-03-24 | |||
| 2015-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $47.00K derived: sum of 2 quarters · filed 2017-03-24 | $119.00K derived: sum of 3 quarters · filed 2017-03-24 | $141.00K 10-K · filed 2017-03-24 | |||
| 2015-09-30 | $24.00K 10-Q · filed 2016-10-26 | $96.00K derived: sum of 2 quarters · filed 2016-10-26 | $118.00K 10-Q · filed 2016-10-26 | $120.00K derived: sum of 4 quarters · filed 2016-10-26 | |||
| 2015-06-30 | $72.00K 10-Q · filed 2016-08-15 | $94.00K 10-Q · filed 2016-08-15 | $96.00K derived: sum of 3 quarters · filed 2016-08-15 | $100.00K derived: sum of 4 quarters · filed 2016-08-15 | |||
| 2015-03-31 | $22.00K 10-Q · filed 2016-05-16 | $24.00K derived: sum of 2 quarters · filed 2016-05-16 | $28.00K derived: sum of 3 quarters · filed 2016-05-16 | $506.00K derived: sum of 4 quarters · filed 2016-05-16 | |||
| 2014-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | $6.00K derived: sum of 2 quarters · filed 2016-03-21 | $484.00K derived: sum of 3 quarters · filed 2016-03-21 | $1.02M 10-K · filed 2016-03-21 | |||
| 2014-09-30 | $4.00K 10-Q · filed 2015-11-13 | $4.15K 10-Q · filed 2014-11-14 | $482.00K derived: sum of 2 quarters · filed 2015-11-13 | $1.02M 10-Q · filed 2015-11-13 | $1.02M 10-Q · filed 2014-11-14 | $1.48M derived: sum of 4 quarters · filed 2015-11-13 | |
| 2014-06-30 | $478.00K 10-Q · filed 2015-08-14 | $477.56K 10-Q · filed 2014-08-14 | $1.02M 10-Q · filed 2015-08-14 | $1.02M 10-Q · filed 2014-08-14 | $1.47M derived: sum of 3 quarters · filed 2015-08-14 | $2.04M derived: sum of 4 quarters · filed 2015-08-14 | |
| 2014-03-31 | $539.00K 10-Q · filed 2015-05-15 | $996.80K derived: sum of 2 quarters · filed 2015-05-15 | $1.56M derived: sum of 3 quarters · filed 2015-05-15 | $2.04M derived: sum of 4 quarters · filed 2015-05-15 | |||
| 2013-12-31 | $457.80K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $1.03M derived: sum of 2 quarters · filed 2015-03-27 | $1.51M derived: sum of 3 quarters · filed 2015-03-27 | $1.96M 10-K · filed 2015-03-27 | |||
| 2013-09-30 | $567.98K 10-Q · filed 2014-11-14 | $1.05M derived: sum of 2 quarters · filed 2014-11-14 | $1.51M 10-Q · filed 2014-11-14 | ||||
| 2013-06-30 | $479.32K 10-Q · filed 2014-08-14 | $937.22K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |